1201593-65-8

Basic information

• Product Name: (S)-2-aMino-3-cyclobutylpropanoic acid
• Synonyms: (alphaS)-alpha-Aminocyclobutanepropanoic acid;Cyclobutanepropanoic acid, α-amino-, (αS)-;L-3-CYCLOBUTYLALANINE;(S)-2-aMino-3-cyclobutylpropanoic acid
• CAS NO: 1201593-65-8
• Molecular Formula: C7H13NO2
• Molecular Weight: 143.18362
• Mol File: 1201593-65-8.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 274.0±23.0 °C(Predicted)
• Appearance: /
• Density: 1.157±0.06 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• PKA: 2.34±0.10(Predicted)
• CAS DataBase Reference: (S)-2-aMino-3-cyclobutylpropanoic acid(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-2-aMino-3-cyclobutylpropanoic acid(1201593-65-8)
• EPA Substance Registry System: (S)-2-aMino-3-cyclobutylpropanoic acid(1201593-65-8)

Safety Data

• Hazardous Substances Data: 1201593-65-8(Hazardous Substances Data)

Usage

General Description

(S)-2-amino-3-cyclobutylpropanoic acid, also known as ACPP, is a chemical compound with the molecular formula C7H13NO2. It is an amino acid derivative that contains a cyclobutane ring in its structure. (S)-2-aMino-3-cyclobutylpropanoic acid is an inhibitor of the enzyme N-acylethanolamine acid amidase (NAAA) and has been investigated for its potential therapeutic applications in treating pain, inflammation, and neurological disorders. ACPP is also a chiral compound, meaning it has two enantiomers, (S)-ACPP and (R)-ACPP, with the (S) form being the biologically active form. This chemical has shown promise in preclinical studies for its ability to modulate the endocannabinoid system and may have potential in the development of new medications.

Upstream product

• 75-56-9 methyloxirane 
• 16408-62-1 cyclobutylmethyl iodide 
• 63659-30-3 cyclobutylmethyl methanesulfonate 
• 4415-82-1 cyclobutanemethanol 
• 13295-53-9 cyclobutylmethyl 4-methylbenzenesulfonate 
• 1068-90-2 2-acetylaminomalonic acid diethyl ester 
• 17247-58-4 (Bromomethyl)cyclobutane 

Relevant articles and documents

Required Immunoproteasome Subunit Inhibition Profile for Anti-Inflammatory Efficacy and Clinical Candidate KZR-616 ((2 S,3 R)- N-((S)-3-(Cyclopent-1-en-1-yl)-1-((R)-2-methyloxiran-2-yl)-1-oxopropan-2-yl)-3-hydroxy-3-(4-methoxyphenyl)-2-((S)-2-(2-morpholinoacetamido)propanamido)propenamide)

Selective immunoproteasome inhibition is a promising approach for treating autoimmune disorders, but optimal proteolytic active site subunit inhibition profiles remain unknown. We reveal here our design of peptide epoxyketone-based selective low molecular mass polypeptide-7 (LMP7) and multicatalytic endopeptidase complex subunit-1 (MECL-1) subunit inhibitors. Utilizing these and our previously disclosed low molecular mass polypeptide-2 (LMP2) inhibitor, we demonstrate a requirement of dual LMP7/LMP2 or LMP7/MECL-1 subunit inhibition profiles for potent cytokine expression inhibition and in vivo efficacy in an inflammatory disease model. These and additional findings toward optimized solubility led the design and selection of KZR-616 disclosed here and presently in clinical trials for treatment of rheumatic disease.

Anticoagulant peptidyl-arginine aldehyde derivatives

The invention relates to new peptidyl-arginine aldehyde compounds of formula (I) Q-D-Xaa-Pro-Arg-H??(I) wherein Q represents an acyl group of formula Q′—OCO, wherein Q′ represents an alkyl-group with 1-3 carbon atoms, D-Xaa represents a 3-cyclobutyl-D-ala